MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.
MVM INVESTS IN EXMOOR PHARMA
MVM led a financing of eXmoor Pharma, an expert cell and gene therapy services company.
Read moreBIOTHERANOSTICS ACQUIRED
Hologic, Inc., a global leader in women's health, announced that it has agreed to acquire Biotheranostics, Inc.
Read moreMVM WINTER 2020 NEWSLETTER
Recent updates regarding MVM team, new investments, and portfolio.
Read moreMVM INVESTS IN GT MEDICAL
MVM led the Series B financing of GT Medical Technologies, a company dedicated to improving the lives of patients with brain tumors.
Read moreVALNEVA ANNOUNCES COVID PARTNERSHIP WITH UK GOVT
UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.
Read moreMVM SUMMER 2020 NEWSLETTER
Recent updates regarding MVM team, new investments, and portfolio.
Read moreMVM INVESTS IN PARAGON 28
MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.
Read moreVALNEVA TO PARTICIPATE IN UK GOVT COVID RESPONSE
Valneva announced an agreement to provide the UK government with up to 100 million doses of its COVID-19 vaccine.
Read moreMVM INVESTS IN MDXHEALTH SA
MVM completed a growth investment in MDxHealth SA, a molecular diagnostic company that markets two proprietary, differentiated tests that optimize the care of patients with prostate cancer.
Read moreMVM INVESTS IN SKYCELL
MVM led the growth investment round in SkyCell, a company that has developed temperature-control technology to safely transport vaccines and biotechnology drugs
Read moreVALNEVA AND PFIZER ANNOUNCE COLLABORATION
Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15
Read moreMVM PARTNERS LLP CLOSES FUND V
MVM Partners announces the closing of a $325 million healthcare fund, MVM V.
Read moreHLS ANNOUNCES HEALTH CANADA APPROVAL FOR VASCEPA®
HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
Read moreBIOTHERANOSTICS LAUNCHES "NOT ANOTHER MINUTE"
Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test
Read moreVERTOS MOTION STUDY ENROLLMENT COMPLETE
Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis
Read moreHLS RECEIVES HEALTH CANADA LICENSE FOR CSAN PRONTO
HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™
Read moreVALNEVA'S PH II LYME STUDIES COMPLETE RECRUITMENT
Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15
Read moreCHEETAH MEDICAL ACQUIRED
Baxter International Inc, a leading global medical products company, has entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies
Read moreMVM INVESTS IN HLS THERAPEUTICS
MVM invests in HLS Therapeutics Inc which acquires and commercializes branded pharmaceuticals in central nervous system and cardiovascular therapeutic areas for the North American market
Read morePOSITIVE RESULTS FOR VALNEVA CHIKUNGUNYA VACCINE
Valneva reports further positive results for Its Chikungunya vaccine candidate
Read moreMVM ANNOUNCES PARTIAL SALE OF ITS AMBIO HOLDING
MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc., a global leader in peptide manufacturing and development to The Carlyle Group
Read moreALEXION TO ACQUIRE WILSON THERAPEUTICS
Wilson Therapeutics AB announces public offer from Alexion Pharmaceuticals
Read more